Remission induction in acute myeloid leukemia

Eytan M. Stein, Martin S. Tallman*

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

16 Scopus citations


Inducing a complete remission (CR) in patients with acute myeloid leukemia is a prerequisite to long-term disease control with subsequent post-remission consolidation chemotherapy or allogeneic hematopoietic stem cell transplantation. The use of 7 days of infusional cytarabine and 3 days of daunorubicin or idarubicin (7 ± 3) has become the standard of care to induce CR, based on clinical trials conducted in the 1980s. Efforts to improve on the CR rate seen with the 7 ± 3 regimen that translates into better overall patient survival have been disappointing. Here we review recent phase III studies of novel induction strategies that show promise in increasing the rate of CR and improving disease outcome.

Original languageEnglish (US)
Pages (from-to)164-170
Number of pages7
JournalInternational journal of hematology
Issue number2
StatePublished - Aug 2012


  • Acute myeloid leukemia
  • Remission

ASJC Scopus subject areas

  • Hematology


Dive into the research topics of 'Remission induction in acute myeloid leukemia'. Together they form a unique fingerprint.

Cite this